Endocrine Abstracts

Background: Neuroendocrine tumors (NETs) and Adrenocortical carcinomas (ACCs) are rare and heterogeneous tumors entities. Advanced NETs and ACC own poor prognosis with less than 40% of five-year survival. There is a need for improved biomarkers to predict disease prognosis and treatment sensitivity. A broad overview of NETs and ACC genetics has never been explored.Aim: To investigate genotype–phenotype correlations on a pan-endocrine cancer level wi...

Introduction: Longitudinal changes in pancreatic neuroendocrine tumor (panNET) cell proliferation correlate with fast disease progression and poor prognosis. The optimal treatment strategy for secondary panNET grade (G)3, that has progressed from a previous low- or intermediate-grade to high-grade panNET G3 is currently unknown. Methods: This was a single center retrospective cohort study, aimed to characterize treatment patterns and outcomes among patie...

Background: TGR represents the percentage change in tumour volume per month (%/m). Previous results from the GREPONET study (A. Lamarca et al, ENETS 2018) showed that TGR measured after 3 months (TGR3m) of starting systemic treatment (ST) or watch and wait (WW) was an early biomarker predicting progression-free survival (PFS) in NETs.Methods: Pts from 7 centres with advanced grade (G) 1/2 NETs from the pancreas (P)/small bowel (SB) initiating ST...